IPCA Laboratories share news, announcements and annual reports
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
IPCA Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,926.20down ₹4.30 (0.22%)BSE ₹1,925.85
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,930.50.
29 Oct: open ₹1,910.50, high ₹1,978.00, low ₹1,910.50
52-week range of traded prices to 29 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48,869 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.31
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.06
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,90,81052.2% delivered
IPCA Laboratories disputes and clarifications
11 filed, newest first.
Dec 2024
19 Dec · Legal
The exchange asked on 18 Dec 2024
Jul 2021
19 Jul · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to announcement dated 16-Jul-2021, regarding Incorporation of Section 8 Company by the name Ipca Foundation. On basis of above the Company is required to clarify following: 1. Percentage of shareholding / control acquired and / or number of shares acquired.The response of the Company is awaited.
Sep 2017
12 Sep · Legal
The exchange asked on 11 Sep 2017
Jul 2016
5 Jul · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to announcement dated 29-Jun-2016: "IPCA Laboratories Limited has informed the Exchange regarding "CRISIL rating for long term bank facility and debt programme of the company".".On basis of above the Company is required to clarify following:1. In case of downward rating, the disclosure may include reasons published by rating agency for such downward rating.The response of the Company is awaited.
Jan 2015
23 Jan · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to recent news item captioned "IPCA Labs Gets US FDA Import Alert For Ratlam Plant". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
29 Dec · Legal
Exchange had sought clarification from IPCA Laboratories Limited with respect to a news item captioned "Indian pharma now under Canada lens". The Company has clarified that "Health Canada has requested the Company to voluntarily quarantine any drugs manufactured at the Company's Indore SEZ, Pithampur formulations manufacturing unit intended for Canadian market as an interim measure and precautionary step in view of the US-FDA audit observations made regarding GMP deficiencies at the said manufacturing unit. The Company does not generate any material business out of the said manufacturing unit from the Canandian market. The Company is fully committed in resolving this issue at the earliest. The Company is also committed to its philosophy of highest quality in manufacturing, operations, systems, intergrity and cGMP culture".26 Dec · Legal
Exchange has sought clarification from IPCA Laboratories Limited with respect to news item captioned "Indian pharma now under Canada lens". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2012